Status:
UNKNOWN
Galactose Supplementation for the Treatment of MOGHE
Lead Sponsor:
Hospital Ruber Internacional
Conditions:
Refractory Epilepsy
SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Eligibility:
All Genders
2-20 years
Phase:
NA
Brief Summary
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recentl...
Eligibility Criteria
Inclusion
- MOGHE diagnosis at histopathological examination of the epilepsy surgery tissue.
- Epilepsy refractoriness or ongoing epileptiform activity at EEG.
Exclusion
- Allergy to galactose or supplement components.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04833322
Start Date
January 15 2021
End Date
October 1 2021
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Ruber Internacional
Madrid, Madrid, Comunidad de, Spain, 28034